Welcome to our dedicated page for Adlai Nortye Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adlai Nortye Ltd. filings document foreign private issuer reports for a clinical-stage oncology biotechnology company whose securities trade as American depositary shares. The company’s Form 6-K reports include pipeline disclosures for AN9025, AN4035, AN8025, AN4005 and AN0025; clinical and regulatory updates; unaudited financial results; corporate presentations; and material agreements.
ANL filings also record capital-structure matters, including private-placement securities purchase agreements and ADS-to-Class A ordinary share references, as well as shareholder meeting materials, proxy cards, board and committee changes, executive appointments, and the adoption of a share incentive plan.
Adlai Nortye Ltd. updates its resale registration for up to 98,577,627 Class A ordinary shares, represented by 32,859,209 ADSs, by changing how certain shares are attributed among selling shareholders. The change reflects that SILV Fund, Ltd. is now listed as the selling shareholder for 2,307,690 Class A ordinary shares originally shown as held under the February 2026 Private Placement by Point72 Associates, LLC. Point72 continues as a selling shareholder for 2,943,396 Class A ordinary shares from the April 2026 Private Placement. The total number of Class A ordinary shares registered for resale remains unchanged, based on 218,578,430 Class A ordinary shares outstanding as of April 21, 2026. The company’s ADSs trade on Nasdaq under the symbol ANL, and the last reported sale price on July 17, 2026 was US$11.53 per ADS.
Adlai Nortye Ltd. reported dosing the first U.S. patient in the intermittent weekly (QW) arm of its ongoing global Phase 1 trial of AN9025, an oral pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations. With this milestone, both the once-daily (QD) and weekly (QW) dose-escalation arms are enrolling, and the company plans to share initial Phase 1 dose-escalation data from the QD arm in 1H27, with a potential early look at the QW arm.
The first-in-human, multicenter, open-label study evaluates the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 and is being run as a multi-regional clinical trial in collaboration with ASK Pharm. Adlai Nortye holds ex-China rights to AN9025, while ASK Pharm retains rights in mainland China, Hong Kong and Macao. AN9025, described as an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential based on preclinical data, is a key part of Adlai Nortye’s broader oncology pipeline alongside additional RAS pathway and PD-1/L1-targeting candidates.
Adlai Nortye Ltd. director Sawhney Roger reports beneficial ownership of 9,838 American Depositary Shares held directly. He also has indirect interests in 4,162 and 4,000 Restricted Share Units through an ESOP, each RSU representing one ADS, with 4,162 RSUs vesting quarterly from August 2026 through August 2027.
Adlai Nortye Ltd. director Ji Ping reported an internal restructuring of holdings involving American Depository Shares. A trust that previously held the position through PECO International Limited distributed 136,667 ADS to Ji Ping’s personal accounts, at which point Ji Ping first acquired beneficial ownership. Following this non-market transaction, Ji Ping directly holds 136,667 ADS in Adlai Nortye, reflecting the outcome of a prior USD 1,344,000 investment made in 2018 that had been placed into the PECO Innovation Trust during the IPO restructuring.
Adlai Nortye Ltd. CFO Ye Xiaofeng reported initial ownership of the company’s American Depositary Shares. The filing shows 159,424 ADS held directly and 31 ADS held indirectly through family members. He also holds stock options over 25,000, 2,584 and 66,667 ADS with exercise prices of 6.6000, 5.4000 and 3.3000 per share, expiring between 2030 and 2032.
Adlai Nortye Ltd. director Tse Alan Ming Lun has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. This filing identifies him as a director of the company but, in the data provided, does not list any reportable transactions or derivative positions.
Adlai Nortye Ltd. CEO and director Lu Yang reported an open-market sale of 10 American Depositary Shares at $13.18 per share. After this small transaction, Lu Yang directly holds 99,990 American Depositary Shares, indicating only a minor change in his overall position.
Adlai Nortye Ltd. CEO Lu Yang has filed an initial ownership report showing existing equity interests in the company. The filing lists an indirect holding of 16,990,000 Class B ordinary shares through a family trust (Archer Future Limited) and a direct holding of 100,000 American Depositary Shares (ADS).
It also discloses three indirect awards of Restricted Share Units (RSUs), each tied to 100,000 ADS, held via an ESOP entity (Nortye Talent Limited. Each RSU represents the right to receive one ADS at a $0.00 exercise price, with vesting dates on January 1, 2027, January 1, 2028, and January 1, 2029. These entries reflect reported holdings, not new market purchases or sales.
Adlai Nortye Ltd. executive Archie Tse, President and Head of R&D, filed an initial ownership report showing beneficial ownership of 50,000 American Depository Shares held directly. The entry is classified as a holding, providing a baseline view of his equity stake in the company.
Adlai Nortye Ltd. - Cormorant Asset Management and Bihua Chen report ownership of 2,897,857 American Depositary Shares, representing 5.19% of the class. The filing states one ADS represents three Class A ordinary shares and references December 31, 2025 outstanding share data.
The statement identifies shared voting and dispositive power over the 2,897,857 ADS and notes a Form 20-F and a Form 6-K cited for outstanding share and private placement figures.